Marcia S. Brose, MD, PhD, FASCO, discusses NTRK gene fusions and identifying patients with thyroid cancer.
Marcia S. Brose, MD, PhD, FASCO, professor, Department of Medical Oncology, Sidney Kimmel Medical College Thomas Jefferson University, vice chair, Department of Medical Oncology Jefferson Northeast, chief of Cancer Services, Sidney Kimmel Cancer Center-Jefferson Northeast, associate director of Community Based Clinical Research, SKCC chair of Hematology/Oncology, Jefferson Torresdale Hospital, discusses NTRK fusions and identifying patients with thyroid cancer.
NTRK gene fusions are key molecular markers in thyroid cancer and are a predictor of a response to a TRK inhibitor. Patients who have this molecular marker are candidates for an additional therapy that those without the marker are ineligible for.
Further, the presence of NTRK fusions in patients with thyroid cancer can aid in diagnosing, determining prognosis, and selecting the optimal treatment plans.
Transcription:
0:08 | We don't really use it so much for the diagnosis and prognosis in thyroid cancer as much as we do it as part of the treatment planning. It's predictive of a response to a TRK inhibitor, and therefore, if somebody has that molecular marker, it identifies them as being a candidate for an additional therapy that a patient without that marker would not be eligible for.
0:36 | We tend to check for NTRK fusions, when we find a patient who needs systemic therapy. In thyroid cancer, particularly in differentiated thyroid cancer, that tends to be once a patient is deemed not curable by either surgery or radioactive iodine alone.
Brose and Laetsch Discuss Rare Actionable Targets in Patients With Thyroid Cancer
January 12th 2023During a Targeted Oncology case-based roundtable event, Marcia S. Brose, MD, PhD, and Theodore W. Laetsch, MD, discussed the data supporting the use of NTRK inhibitors in a patient with metastatic papillary thyroid cancer.
Read More
FDA Clears Phase 1/2 Study of ABT-101 in Non–Small Cell Lung Cancer
September 14th 2022The FDA has granted approval for an investigational new drug protocol amendment for ABT-101, a mutant selective tyrosine kinase inhibitor which has shown superior selectivity against HER2 exon 20 mutations in NSCLC in preclinical studies.
Read More
Larotrectinib Demonstrates Robust Responses in TRK Fusion-Positive Lung Cancer
September 6th 2022In an interview with Targeted Oncologyy, David S. Hong, MD, discussed an updated analysis of larotrectinib and the data supporting the agent for the treatment of TRK fusion-positive lung tumors.
Read More